PRIME MEDICINE INC. news, videos and press releases
For more news please use our advanced search feature.
PRIME MEDICINE INC. - More news...
PRIME MEDICINE INC. - More news...
- Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates
- Prime Medicine to Participate in Upcoming Investor Conferences
- Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress
- Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings
- Prime Medicine Unveils Strategically Focused Pipeline
- Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
- Prime Medicine to Participate in Upcoming Investor Conferences
- Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates
- Prime Medicine to Present at Upcoming Investor Conferences
- Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
- Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
- Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)
- Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference
- Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
- Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings
- Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
- Prime Medicine to Participate in Upcoming Investor Conferences
- Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
- Prime Medicine Announces Pricing of Upsized Public Offering
- Prime Medicine Announces Proposed Public Offering of Common Stock
- Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis
- Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer
- Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference
- Prime Medicine to Present at Upcoming Investor Conferences
- Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates
- Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b
- Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases
- Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences
- Prime Medicine to Present at Upcoming Investor Conferences
